Deloitte’s Center for Health Solutions reports that the cell, gene, and RNA therapies sector is shifting from niche launches to broader, sustainable patient care. In interviews with 14 senior industry executives between December 2024 and July 2025, Deloitte found that companies are expanding into new areas such as autoimmune disorders, type 1 diabetes, and neurological diseases. Despite a drop in investment, from $23 billion in 2021 to $15 billion in 2024, the field shows strength, with more than 140 approved therapies and 4,000 under development, and a projected compound annual growth rate of 18% through 2033.
Operational improvements are emerging across manufacturing, R&D, and commercialization. Executives reported gains in automation, with robotics and modular digital platforms helping reduce production times and costs. Safety has improved, particularly for cell therapies, with fewer severe immune reactions as researchers better identify biomarkers. On the business side, they note that “Business models and supporting infrastructure are still catching up with scientific innovation,” and that the industry needs sustained investments in manufacturing, supply chains, and delivery infrastructure. To make these therapies more accessible, leaders advocate for innovative payment models, broader distribution networks, and partnerships across pharma, providers, and payers.